The resource-draining experience of revoking Avastin’s breast cancer claim means that any new expedited or “progressive approval” pathway should include a quicker, easier withdrawal mechanism, according to Center for Biologics Evaluation and Research Director Karen Midthun.
Speaking at Elsevier Business Intelligence’s FDA/CMS Summit on Dec. 8, Midthun suggested that the agency’s resources should be taken into...